Clinical Trial Update: A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients [Phase 2]

View source ↗

Summary

A Phase 2, open-label trial evaluating ABSK-011 in combination with atezolizumab or standard of care in patients with hepatocellular carcinoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABSK-011
• Atezolizumab (atezolizumab)

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ENROLLING_BY_INVITATION